betaine has been researched along with Fatty Liver in 62 studies
glycine betaine : The amino acid betaine derived from glycine.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that lower folate, choline, betaine, and glutathione (GSH) concentrations but higher total homocysteine and trimethylamine N-oxide concentrations are associated with fatty liver (FL) in postmenopausal women." | 8.12 | Lower plasma glutathione, choline, and betaine concentrations are associated with fatty liver in postmenopausal women. ( Chmurzynska, A; Muzsik-Kazimierska, A; Nikrandt, G; Szwengiel, A, 2022) |
| "BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet." | 7.88 | Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018) |
| "Betaine alleviates high-fat diet-induced fatty liver and prenatal betaine programs offspring hepatic lipid metabolism." | 7.85 | In ovo injection of betaine alleviates corticosterone-induced fatty liver in chickens through epigenetic modifications. ( Cai, D; Hu, Y; Idriss, AA; Jia, Y; Liu, J; Omer, NA; Sun, Q; Zhao, R, 2017) |
| " Promising beneficial effects of betaine supplementation on nonalcoholic fatty liver disease (NAFLD) have been reported in both clinical investigations and experimental studies; however, data related to betaine therapy in NAFLD are still limited." | 7.76 | Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. ( Fantuzzi, G; Pini, M; Song, Z; Wang, Z; Yao, T; Zhou, Z, 2010) |
| "We evaluated the effects of betaine supplementation on liver weight, liver/body weight, serum parameters and morphological changes." | 7.75 | The effects of dietary betaine supplementation on fatty liver performance, serum parameters, histological changes, methylation status and the mRNA expression level of Spot14alpha in Landes goose fatty liver. ( Dodson, MV; Li, QF; Li, XB; Su, SY; Wang, HW; Xie, Z, 2009) |
| "We recently reported that fatty liver and hypertriglyceridemia are easily induced by the administration of an inhibitor of fatty acid oxidation (emeriamine; (R)-3-amino-4-trimethylaminobutyric acid) to fasting rats, and that these conditions are not accompanied by the increased de novo synthesis of fatty acid [J." | 7.69 | Effects of refeeding diets on emeriamine-induced fatty liver in fasting rats. ( Fujiwara, M; Fukuda, N; Hamamoto, H; Maeda, H; Miyamoto, K, 1996) |
| "Betaine was shown to be a potential agent for the treatment of hepatopathy associated with SBS, which was evidenced by NMR, although the markers for hepatic lesion have not presented significant decrease." | 6.79 | Betaine: a potential agent for the treatment of hepatopathy associated with short bowel syndrome. ( Domenici, F; Elias, J; Teixeira Araújo, G; Vannucchi, H, 2014) |
| "Betaine is a safe and well tolerated drug that leads to a significant biochemical and histological improvement in patients with NASH." | 6.70 | Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. ( Abdelmalek, MF; Angulo, P; Jorgensen, RA; Lindor, KD; Sylvestre, PB, 2001) |
| "Betaine treatment reversed the inhibition of hepatic insulin signaling in mHF and in insulin-resistant HepG2 cells, including normalization of insulin receptor substrate 1 (IRS1) phosphorylation and of downstream signaling pathways for gluconeogenesis and glycogen synthesis." | 5.36 | Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. ( Bottiglieri, T; Caudill, MA; French, SW; Kathirvel, E; Morgan, K; Morgan, TR; Nandgiri, G; Sandoval, BC, 2010) |
| "Nonalcoholic fatty liver is involved in the development of nonalcoholic steatohepatitis and chronic liver injury." | 5.35 | Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. ( Jung, YS; Kim, SJ; Kim, YC; Kwon, DY; Park, HK; Park, JH, 2009) |
| "Betaine has a lipotropic effect, which is associated with a reduction in homocysteine, an increase in ApoA-I and an amelioration of the atherogenic risk profile." | 5.34 | Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. ( Cohn, J; Jiang, H; Maclean, KN; Mikael, LG; Rozen, R; Schwahn, BC; Wang, XL; Wu, Q, 2007) |
| " We hypothesized that lower folate, choline, betaine, and glutathione (GSH) concentrations but higher total homocysteine and trimethylamine N-oxide concentrations are associated with fatty liver (FL) in postmenopausal women." | 4.12 | Lower plasma glutathione, choline, and betaine concentrations are associated with fatty liver in postmenopausal women. ( Chmurzynska, A; Muzsik-Kazimierska, A; Nikrandt, G; Szwengiel, A, 2022) |
| "BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet." | 3.88 | Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018) |
| "We have shown previously that in ovo betaine injection can prevent nonalcoholic fatty liver induced by glucocorticoid exposure in chickens; yet it remains unknown whether feeding betaine to laying hens may exert similar effects in their progeny." | 3.88 | Corticosterone-Induced Lipogenesis Activation and Lipophagy Inhibition in Chicken Liver Are Alleviated by Maternal Betaine Supplementation. ( Abobaker, H; Hou, Z; Hu, Y; Omer, NA; Sun, Q; Zhao, R; Zong, Y, 2018) |
| "Betaine alleviates high-fat diet-induced fatty liver and prenatal betaine programs offspring hepatic lipid metabolism." | 3.85 | In ovo injection of betaine alleviates corticosterone-induced fatty liver in chickens through epigenetic modifications. ( Cai, D; Hu, Y; Idriss, AA; Jia, Y; Liu, J; Omer, NA; Sun, Q; Zhao, R, 2017) |
| " Promising beneficial effects of betaine supplementation on nonalcoholic fatty liver disease (NAFLD) have been reported in both clinical investigations and experimental studies; however, data related to betaine therapy in NAFLD are still limited." | 3.76 | Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. ( Fantuzzi, G; Pini, M; Song, Z; Wang, Z; Yao, T; Zhou, Z, 2010) |
| "We evaluated the effects of betaine supplementation on liver weight, liver/body weight, serum parameters and morphological changes." | 3.75 | The effects of dietary betaine supplementation on fatty liver performance, serum parameters, histological changes, methylation status and the mRNA expression level of Spot14alpha in Landes goose fatty liver. ( Dodson, MV; Li, QF; Li, XB; Su, SY; Wang, HW; Xie, Z, 2009) |
| "We recently reported that fatty liver and hypertriglyceridemia are easily induced by the administration of an inhibitor of fatty acid oxidation (emeriamine; (R)-3-amino-4-trimethylaminobutyric acid) to fasting rats, and that these conditions are not accompanied by the increased de novo synthesis of fatty acid [J." | 3.69 | Effects of refeeding diets on emeriamine-induced fatty liver in fasting rats. ( Fujiwara, M; Fukuda, N; Hamamoto, H; Maeda, H; Miyamoto, K, 1996) |
| "Untreated steatosis can progress to steatohepatitis, fibrosis and/or cirrhosis." | 2.82 | Betaine in ameliorating alcohol-induced hepatic steatosis. ( Mehta, KJ; Rehman, A, 2022) |
| "Betaine was shown to be a potential agent for the treatment of hepatopathy associated with SBS, which was evidenced by NMR, although the markers for hepatic lesion have not presented significant decrease." | 2.79 | Betaine: a potential agent for the treatment of hepatopathy associated with short bowel syndrome. ( Domenici, F; Elias, J; Teixeira Araújo, G; Vannucchi, H, 2014) |
| "Betaine is a safe and well tolerated drug that leads to a significant biochemical and histological improvement in patients with NASH." | 2.70 | Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. ( Abdelmalek, MF; Angulo, P; Jorgensen, RA; Lindor, KD; Sylvestre, PB, 2001) |
| " Adverse events were recorded in 10% of verum-treated patients and in 7% under placebo (no significant difference)." | 2.69 | Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. ( Miglio, F; Rovati, LC; Santoro, A; Setnikar, I, 2000) |
| "Betaine is a significant determinant of plasma tHcy, particularly in case of folate deficiency, methionine load, or alcohol consumption." | 2.49 | The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway. ( Obeid, R, 2013) |
| "Nonalcoholic steatohepatitis (NASH), a more serious form of NAFLD, can proceed to cirrhosis and even hepatocellular carcinoma." | 2.44 | Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. ( Barve, S; Cave, M; Deaciuc, I; Joshi-Barve, S; McClain, C; Mendez, C; Song, Z, 2007) |
| "Non-alcoholic steatohepatitis once considered a benign process is now known to lead to progressive fibrosis and cirrhosis." | 2.43 | Review article: Drug therapy for non-alcoholic fatty liver disease. ( Comar, KM; Sterling, RK, 2006) |
| "Choline deficiency has been well studied in the context of liver disease; however, less is known about the effects of choline supplementation in HCC." | 1.56 | Dietary Choline Supplementation Attenuates High-Fat-Diet-Induced Hepatocellular Carcinoma in Mice. ( Allende, DS; Brown, AL; Conrad, K; Gromovsky, AD; Helsley, RN; Neumann, CK; Owens, AP; Tranter, M; Zhang, R, 2020) |
| "Betaine plays a pivotal role in the regulation of methylogenesis." | 1.46 | Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. ( Castaño, GO; Mirshahi, F; Pirola, CJ; Puri, P; Sanyal, AJ; Scian, R; Sookoian, S, 2017) |
| "Betaine is a major water-soluble component of Lycium chinensis." | 1.43 | Molecular Mechanism of Betaine on Hepatic Lipid Metabolism: Inhibition of Forkhead Box O1 (FoxO1) Binding to Peroxisome Proliferator-Activated Receptor Gamma (PPARγ). ( An, HJ; Choi, JS; Chung, HY; Chung, KW; Kim, DH; Kim, MJ; Lee, B; Lee, EK; Park, JW; Park, MH; Yu, BP, 2016) |
| "Betaine is a methyl donor and has been considered to be a lipotropic agent." | 1.40 | Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet. ( Chen, XL; Ling, WH; Liu, Y; Wang, LJ; Yang, Y; Zhang, HW; Zheng, RD; Zhou, JY; Zhu, CH; Zhu, HL, 2014) |
| "Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials." | 1.37 | Betaine and nonalcoholic steatohepatitis: back to the future? ( Mukherjee, S, 2011) |
| "Betaine treatment reversed the inhibition of hepatic insulin signaling in mHF and in insulin-resistant HepG2 cells, including normalization of insulin receptor substrate 1 (IRS1) phosphorylation and of downstream signaling pathways for gluconeogenesis and glycogen synthesis." | 1.36 | Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. ( Bottiglieri, T; Caudill, MA; French, SW; Kathirvel, E; Morgan, K; Morgan, TR; Nandgiri, G; Sandoval, BC, 2010) |
| "Nonalcoholic fatty liver is involved in the development of nonalcoholic steatohepatitis and chronic liver injury." | 1.35 | Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. ( Jung, YS; Kim, SJ; Kim, YC; Kwon, DY; Park, HK; Park, JH, 2009) |
| "Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease." | 1.35 | Pharmacologic therapy of non-alcoholic steatohepatitis. ( Ratziu, V; Zelber-Sagi, S, 2009) |
| "Betaine has a lipotropic effect, which is associated with a reduction in homocysteine, an increase in ApoA-I and an amelioration of the atherogenic risk profile." | 1.34 | Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. ( Cohn, J; Jiang, H; Maclean, KN; Mikael, LG; Rozen, R; Schwahn, BC; Wang, XL; Wu, Q, 2007) |
| "Betaine was supplemented in the drinking water at a concentration of 1% (wt/vol) (anhydrous)." | 1.34 | Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. ( Chen, T; Deaciuc, I; Hill, D; McClain, CJ; Song, M; Song, Z; Zhou, Z, 2007) |
| "A betaine treatment protected primary mouse hepatocytes from a homocysteine-induced increase in GRP78 and cell death but not a tunicamycin-induced increase." | 1.34 | Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. ( Chan, C; Ji, C; Kaplowitz, N; Kuhlenkamp, J; Shinohara, M, 2007) |
| "Betaine treatment together with ethanol in guinea pigs is found to decrease hepatic triglyceride, lipid peroxide levels and serum transaminase activities and to increase GSH levels." | 1.32 | The effect of betaine treatment on triglyceride levels and oxidative stress in the liver of ethanol-treated guinea pigs. ( Balkan, J; Cevikbaş, U; Koçak-Toker, N; Küçük, M; Oztezcan, S; Uysal, M, 2004) |
| " The results indicate that oral betaine either improves recovery or reduces the toxic effects of CCl4 on cell organelles in liver cells of male Han-Wistar rats." | 1.31 | Reduction of carbon tetrachloride-induced hepatotoxic effects by oral administration of betaine in male Han-Wistar rats: a morphometric histological study. ( Junnila, M; Lindberg, LA; Rahko, T; Sukura, A, 2000) |
| "Juvenile visceral steatosis (JVS) mice are associated with systemic carnitine deficiency (Kuwajima, et al." | 1.29 | Carnitine transport defect in fibroblasts of juvenile visceral steatosis (JVS) mouse. ( Hanafusa, T; Harashima, H; Hayakawa, J; Kuwajima, M; Lu, K; Matsuzawa, Y; Miyagawa, J; Mizuno, A; Murakami, T; Nakajima, H; Namba, M; Ono, A; Sato, I; Shima, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (17.74) | 18.7374 |
| 1990's | 3 (4.84) | 18.2507 |
| 2000's | 21 (33.87) | 29.6817 |
| 2010's | 21 (33.87) | 24.3611 |
| 2020's | 6 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Rehman, A | 1 |
| Mehta, KJ | 1 |
| Chang, TY | 1 |
| Wu, CH | 1 |
| Chang, CY | 2 |
| Lee, FJ | 1 |
| Wang, BW | 1 |
| Doong, JY | 1 |
| Lin, YS | 1 |
| Kuo, CS | 1 |
| Huang, RS | 1 |
| Muzsik-Kazimierska, A | 1 |
| Szwengiel, A | 2 |
| Nikrandt, G | 1 |
| Chmurzynska, A | 2 |
| Brown, AL | 1 |
| Conrad, K | 1 |
| Allende, DS | 1 |
| Gromovsky, AD | 1 |
| Zhang, R | 1 |
| Neumann, CK | 1 |
| Owens, AP | 1 |
| Tranter, M | 1 |
| Helsley, RN | 1 |
| Blachier, F | 1 |
| Andriamihaja, M | 1 |
| Blais, A | 1 |
| Młodzik-Czyżewska, MA | 1 |
| Malinowska, AM | 1 |
| Küskü-Kiraz, Z | 1 |
| Genc, S | 1 |
| Bekpınar, S | 1 |
| Ünlücerci, Y | 1 |
| Çevik, A | 1 |
| Olgaç, V | 1 |
| Gürdöl, F | 1 |
| Uysal, M | 2 |
| Hu, Y | 3 |
| Sun, Q | 2 |
| Hou, Z | 1 |
| Zong, Y | 1 |
| Omer, NA | 2 |
| Abobaker, H | 1 |
| Zhao, R | 2 |
| Zhang, W | 1 |
| Wang, LW | 1 |
| Wang, LK | 1 |
| Li, X | 1 |
| Zhang, H | 1 |
| Luo, LP | 1 |
| Song, JC | 1 |
| Gong, ZJ | 1 |
| Obeid, R | 1 |
| Wang, LJ | 1 |
| Zhang, HW | 1 |
| Zhou, JY | 1 |
| Liu, Y | 1 |
| Yang, Y | 1 |
| Chen, XL | 1 |
| Zhu, CH | 1 |
| Zheng, RD | 1 |
| Ling, WH | 1 |
| Zhu, HL | 1 |
| Varatharajalu, R | 1 |
| Garige, M | 1 |
| Leckey, LC | 1 |
| Arellanes-Robledo, J | 1 |
| Reyes-Gordillo, K | 1 |
| Shah, R | 1 |
| Lakshman, MR | 1 |
| Teixeira Araújo, G | 1 |
| Domenici, F | 1 |
| Elias, J | 1 |
| Vannucchi, H | 1 |
| Deminice, R | 1 |
| da Silva, RP | 1 |
| Lamarre, SG | 1 |
| Kelly, KB | 1 |
| Jacobs, RL | 3 |
| Brosnan, ME | 1 |
| Brosnan, JT | 1 |
| Ejaz, A | 1 |
| Martinez-Guino, L | 1 |
| Goldfine, AB | 1 |
| Ribas-Aulinas, F | 1 |
| De Nigris, V | 1 |
| Ribó, S | 1 |
| Gonzalez-Franquesa, A | 1 |
| Garcia-Roves, PM | 1 |
| Li, E | 1 |
| Dreyfuss, JM | 1 |
| Gall, W | 1 |
| Kim, JK | 1 |
| Bottiglieri, T | 2 |
| Villarroya, F | 1 |
| Gerszten, RE | 1 |
| Patti, ME | 1 |
| Lerin, C | 1 |
| Kim, DH | 1 |
| Lee, B | 1 |
| Kim, MJ | 1 |
| Park, MH | 1 |
| An, HJ | 1 |
| Lee, EK | 1 |
| Chung, KW | 1 |
| Park, JW | 1 |
| Yu, BP | 1 |
| Choi, JS | 1 |
| Chung, HY | 1 |
| Sookoian, S | 1 |
| Puri, P | 1 |
| Castaño, GO | 1 |
| Scian, R | 1 |
| Mirshahi, F | 1 |
| Sanyal, AJ | 1 |
| Pirola, CJ | 1 |
| Liu, J | 1 |
| Jia, Y | 1 |
| Cai, D | 1 |
| Idriss, AA | 1 |
| Tsai, MT | 1 |
| Chen, YJ | 2 |
| Chen, CY | 1 |
| Tsai, MH | 1 |
| Han, CL | 1 |
| Mersmann, HJ | 1 |
| Ding, ST | 1 |
| Kwon, DY | 1 |
| Jung, YS | 1 |
| Kim, SJ | 1 |
| Park, HK | 1 |
| Park, JH | 1 |
| Kim, YC | 1 |
| Su, SY | 1 |
| Dodson, MV | 1 |
| Li, XB | 1 |
| Li, QF | 1 |
| Wang, HW | 1 |
| Xie, Z | 1 |
| Ratziu, V | 1 |
| Zelber-Sagi, S | 1 |
| Abdelmalek, MF | 2 |
| Sanderson, SO | 1 |
| Angulo, P | 2 |
| Soldevila-Pico, C | 1 |
| Liu, C | 1 |
| Peter, J | 1 |
| Keach, J | 1 |
| Cave, M | 2 |
| Chen, T | 2 |
| McClain, CJ | 2 |
| Lindor, KD | 2 |
| Wang, Z | 1 |
| Yao, T | 1 |
| Pini, M | 1 |
| Zhou, Z | 2 |
| Fantuzzi, G | 1 |
| Song, Z | 3 |
| Zhao, Y | 1 |
| Koonen, DP | 1 |
| Sletten, T | 1 |
| Su, B | 1 |
| Lingrell, S | 1 |
| Cao, G | 1 |
| Peake, DA | 1 |
| Kuo, MS | 1 |
| Proctor, SD | 1 |
| Kennedy, BP | 1 |
| Dyck, JR | 1 |
| Vance, DE | 2 |
| Christensen, KE | 1 |
| Wu, Q | 2 |
| Wang, X | 1 |
| Deng, L | 1 |
| Caudill, MA | 2 |
| Rozen, R | 2 |
| Kathirvel, E | 1 |
| Morgan, K | 1 |
| Nandgiri, G | 1 |
| Sandoval, BC | 1 |
| French, SW | 1 |
| Morgan, TR | 1 |
| Cordero, P | 1 |
| Campion, J | 1 |
| Milagro, FI | 1 |
| Martínez, JA | 1 |
| Niebergall, LJ | 1 |
| Chaba, T | 1 |
| Mukherjee, S | 1 |
| Kawakami, S | 1 |
| Han, KH | 1 |
| Nakamura, Y | 1 |
| Shimada, K | 1 |
| Kitano, T | 1 |
| Aritsuka, T | 1 |
| Nagura, T | 1 |
| Ohba, K | 1 |
| Nakamura, K | 1 |
| Fukushima, M | 1 |
| Patrick, L | 1 |
| BRIGNON, J | 2 |
| WOLFF, R | 3 |
| BRIGNON, JJ | 1 |
| RAUBER, G | 1 |
| WILGRAM, GF | 1 |
| LUCAS, CC | 1 |
| BEST, CH | 1 |
| GEER, BW | 1 |
| VOVIS, GF | 1 |
| Houghton, WC | 1 |
| Yang, S | 1 |
| Koteish, A | 1 |
| Lin, H | 1 |
| Huang, J | 1 |
| Roskams, T | 1 |
| Dawson, V | 1 |
| Diehl, AM | 1 |
| Balkan, J | 1 |
| Oztezcan, S | 1 |
| Küçük, M | 1 |
| Cevikbaş, U | 1 |
| Koçak-Toker, N | 1 |
| Kharbanda, KK | 1 |
| Rogers, DD | 1 |
| Mailliard, ME | 1 |
| Siford, GL | 1 |
| Barak, AJ | 1 |
| Beckenhauer, HC | 1 |
| Sorrell, MF | 1 |
| Tuma, DJ | 1 |
| Serkova, NJ | 1 |
| Jackman, M | 1 |
| Brown, JL | 1 |
| Liu, T | 1 |
| Hirose, R | 1 |
| Roberts, JP | 1 |
| Maher, JJ | 1 |
| Niemann, CU | 1 |
| Comar, KM | 1 |
| Sterling, RK | 1 |
| Argo, CK | 1 |
| Al-Osaimi, AM | 1 |
| Caldwell, SH | 1 |
| Deaciuc, I | 2 |
| Mendez, C | 1 |
| Joshi-Barve, S | 1 |
| Barve, S | 1 |
| McClain, C | 1 |
| Schwahn, BC | 1 |
| Wang, XL | 1 |
| Mikael, LG | 1 |
| Cohn, J | 1 |
| Jiang, H | 1 |
| Maclean, KN | 1 |
| Song, M | 1 |
| Hill, D | 1 |
| Ji, C | 1 |
| Shinohara, M | 1 |
| Kuhlenkamp, J | 1 |
| Chan, C | 1 |
| Kaplowitz, N | 1 |
| Kuwajima, M | 1 |
| Lu, K | 1 |
| Harashima, H | 1 |
| Ono, A | 1 |
| Sato, I | 1 |
| Mizuno, A | 1 |
| Murakami, T | 1 |
| Nakajima, H | 1 |
| Miyagawa, J | 1 |
| Namba, M | 1 |
| Hanafusa, T | 1 |
| Hayakawa, J | 1 |
| Matsuzawa, Y | 1 |
| Shima, K | 1 |
| Maeda, H | 2 |
| Fujiwara, M | 2 |
| Fujita, K | 1 |
| Fukuda, N | 2 |
| Miyamoto, K | 1 |
| Hamamoto, H | 1 |
| Junnila, M | 1 |
| Rahko, T | 1 |
| Sukura, A | 1 |
| Lindberg, LA | 1 |
| Miglio, F | 1 |
| Rovati, LC | 1 |
| Santoro, A | 1 |
| Setnikar, I | 1 |
| Neuschwander-Tetri, BA | 1 |
| Jorgensen, RA | 1 |
| Sylvestre, PB | 1 |
| Semmler, F | 1 |
| Babucke, G | 1 |
| Sarre, B | 1 |
| Hilt, G | 1 |
| Tuzin, P | 1 |
| Gäbler, H | 1 |
| Ferruccio, S | 1 |
| Cachin, M | 1 |
| Pergola, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF[NCT00406536] | Phase 2 | 110 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Comparison of Standard Therapy,Peginterferon Alpha-2a + Ribavirin for 48 Weeks VS Peginterferon Alph-2a + Ribavirin + Betaine for 12 Weeks Followed by 36 Weeks Standard Therapy in Untreated Adults With Chronic Hepatitis C Genotype 1[NCT00571714] | 0 participants (Actual) | Interventional | 2008-04-01 | Withdrawn (stopped due to lack of enrollment) | |||
| Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria[NCT00283387] | Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months.~Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period." (NCT00283387)
Timeframe: baseline, 2 months, 6 months
| Intervention | umol/mg (Mean) |
|---|---|
| Betaine | 1.43 |
| Placebo | 1.04 |
7 reviews available for betaine and Fatty Liver
| Article | Year |
|---|---|
Betaine in ameliorating alcohol-induced hepatic steatosis.
Topics: Animals; Betaine; Fatty Liver; Lipogenesis; Liver; Sterol Regulatory Element Binding Protein 1 | 2022 |
Sulfur-Containing Amino Acids and Lipid Metabolism.
Topics: Amino Acids, Sulfur; Animals; Atherosclerosis; Betaine; Cholesterol; Cysteine; Dietary Proteins; Die | 2020 |
The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway.
Topics: Animals; Betaine; Betaine-Homocysteine S-Methyltransferase; Choline; Dietary Supplements; Disease Mo | 2013 |
Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine.
Topics: Antioxidants; Betaine; Fatty Liver; Female; Humans; Insulin Resistance; Lipotropic Agents; Liver; Ma | 2002 |
Review article: Drug therapy for non-alcoholic fatty liver disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic Acid; Betaine; Cholagogues and Chol | 2006 |
Therapy of NAFLD: antioxidants and cytoprotective agents.
Topics: Acetylcysteine; Antioxidants; Betaine; Cholagogues and Choleretics; Disease Progression; Fatty Liver | 2006 |
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition.
Topics: Betaine; Cytokines; Dietary Supplements; Environmental Exposure; Fatty Liver; Female; Humans; Insuli | 2007 |
5 trials available for betaine and Fatty Liver
| Article | Year |
|---|---|
Betaine: a potential agent for the treatment of hepatopathy associated with short bowel syndrome.
Topics: Adult; Aged; Betaine; Fatty Liver; Female; Gastrointestinal Agents; Humans; Liver Diseases; Male; Mi | 2014 |
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.
Topics: Adipokines; Adult; Aged; Betaine; Cytokines; Double-Blind Method; Fatty Liver; Female; Humans; Male; | 2009 |
Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study.
Topics: Adult; Betaine; Double-Blind Method; Dyspepsia; Fatty Liver; Female; Glucuronates; Hepatomegaly; Hum | 2000 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Topics: Adult; Betaine; Fatty Liver; Female; Hepatitis; Humans; Lipotropic Agents; Male; Middle Aged; Pilot | 2001 |
[Treatment of liver diseases, especially of fatty liver with betaine citrate].
Topics: Adult; Betaine; Clinical Trials as Topic; Drug Evaluation; Fatty Liver; Humans; Liver Diseases | 1977 |
50 other studies available for betaine and Fatty Liver
| Article | Year |
|---|---|
Optimal Dietary Intake Composition of Choline and Betaine Is Associated with Minimized Visceral Obesity-Related Hepatic Steatosis in a Case-Control Study.
Topics: Adiposity; Aged; Betaine; Biomarkers; Body Composition; Case-Control Studies; Choline; Diet Records; | 2022 |
Lower plasma glutathione, choline, and betaine concentrations are associated with fatty liver in postmenopausal women.
Topics: Betaine; Biomarkers; Choline; Fatty Liver; Female; Folic Acid; Glutathione; Homocysteine; Humans; Po | 2022 |
Dietary Choline Supplementation Attenuates High-Fat-Diet-Induced Hepatocellular Carcinoma in Mice.
Topics: Animals; Betaine; Choline; Diet, High-Fat; Dietary Supplements; DNA, Mitochondrial; Fatty Liver; Gen | 2020 |
Comparison of Associations between One-Carbon Metabolism, Lipid Metabolism, and Fatty Liver Markers in Normal-Weight and Overweight People Aged 20-40 Years.
Topics: Adult; Betaine; Carbon; Choline; Fatty Liver; Humans; Lipid Metabolism; Overweight; Phosphatidyletha | 2021 |
Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet.
Topics: Animals; Arginine; Atherosclerosis; Betaine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Diet | 2018 |
Corticosterone-Induced Lipogenesis Activation and Lipophagy Inhibition in Chicken Liver Are Alleviated by Maternal Betaine Supplementation.
Topics: Animals; Betaine; Chickens; Corticosterone; Dietary Supplements; Disease Models, Animal; DNA Methyla | 2018 |
Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and Toll-like receptor 4 expression in rats.
Topics: Animals; Betaine; Chemical and Drug Induced Liver Injury; Cytokines; Dietary Fats; Fatty Liver; Fema | 2013 |
Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet.
Topics: Animals; Betaine; Diet, High-Fat; DNA Methylation; Fatty Liver; Male; Mice; Mice, Inbred C57BL; Prom | 2014 |
Adverse signaling of scavenger receptor class B1 and PGC1s in alcoholic hepatosteatosis and steatohepatitis and protection by betaine in rat.
Topics: Adiponectin; Alanine Transaminase; Animals; Betaine; Diet, High-Fat; Ethanol; Fatty Liver; Fatty Liv | 2014 |
Betaine supplementation prevents fatty liver induced by a high-fat diet: effects on one-carbon metabolism.
Topics: Acyltransferases; Animals; Betaine; Carbon; Diet, High-Fat; Dietary Supplements; Fatty Liver; Glycin | 2015 |
Dietary Betaine Supplementation Increases Fgf21 Levels to Improve Glucose Homeostasis and Reduce Hepatic Lipid Accumulation in Mice.
Topics: Adult; Animals; Betaine; Cells, Cultured; Dietary Supplements; Fatty Liver; Female; Fibroblast Growt | 2016 |
Molecular Mechanism of Betaine on Hepatic Lipid Metabolism: Inhibition of Forkhead Box O1 (FoxO1) Binding to Peroxisome Proliferator-Activated Receptor Gamma (PPARγ).
Topics: Animals; Betaine; Fatty Liver; Forkhead Box Protein O1; Hep G2 Cells; Humans; Lipid Metabolism; Lipo | 2016 |
Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency.
Topics: Adult; Argentina; Betaine; Biomarkers; Case-Control Studies; Dimethylglycine Dehydrogenase; Disease | 2017 |
In ovo injection of betaine alleviates corticosterone-induced fatty liver in chickens through epigenetic modifications.
Topics: Animals; Betaine; Body Weight; Chickens; Corticosterone; DNA Methylation; DNA, Mitochondrial; Eating | 2017 |
Identification of Potential Plasma Biomarkers for Nonalcoholic Fatty Liver Disease by Integrating Transcriptomics and Proteomics in Laying Hens.
Topics: Animals; Betaine; Biomarkers; Bird Diseases; Chickens; Docosahexaenoic Acids; Fatty Liver; Female; P | 2017 |
Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats.
Topics: Amino Acids, Sulfur; Animals; Betaine; Diet; Dietary Fats; Dietary Supplements; Fatty Liver; Liver; | 2009 |
The effects of dietary betaine supplementation on fatty liver performance, serum parameters, histological changes, methylation status and the mRNA expression level of Spot14alpha in Landes goose fatty liver.
Topics: Animals; Betaine; Body Weight; Diet; DNA Methylation; Fatty Liver; Geese; Liver; Male; Nuclear Prote | 2009 |
Pharmacologic therapy of non-alcoholic steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Anti-Obesity Agents; Antioxidants; Betaine; Cholagogues and | 2009 |
Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease.
Topics: Adipokines; Adipose Tissue; Animals; Betaine; Dietary Fats; Endoplasmic Reticulum; Fatty Liver; Insu | 2010 |
Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity.
Topics: Animals; Betaine; Choline; Diet; Dietary Fats; Dietary Supplements; Energy Metabolism; Fatty Liver; | 2010 |
Steatosis in mice is associated with gender, folate intake, and expression of genes of one-carbon metabolism.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Animals; Betaine; Betaine-Homocysteine S- | 2010 |
Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine.
Topics: Administration, Oral; Animals; Betaine; Blotting, Western; Cells, Cultured; Dietary Fats; Fatty Live | 2010 |
Dietary supplementation with methyl donor groups could prevent nonalcoholic fatty liver.
Topics: Animals; Betaine; Choline; Dietary Fats; Dietary Sucrose; Dietary Supplements; Disease Models, Anima | 2011 |
Phosphatidylcholine protects against steatosis in mice but not non-alcoholic steatohepatitis.
Topics: Adenoviridae; Animals; Betaine; Ceramides; Choline-Phosphate Cytidylyltransferase; Cytidine Diphosph | 2011 |
Betaine and nonalcoholic steatohepatitis: back to the future?
Topics: Animals; Betaine; Clinical Trials as Topic; Fatty Liver; Humans; Insulin Resistance; Liver Transplan | 2011 |
Effects of dietary supplementation with betaine on a nonalcoholic steatohepatitis (NASH) mouse model.
Topics: Alanine Transaminase; Animals; Betaine; Body Weight; Diet, High-Fat; Dietary Fats; Dietary Supplemen | 2012 |
Betaine. Monograph.
Topics: Betaine; Cardiovascular Diseases; Fatty Liver; Homocysteine; Homocystinuria; Humans; Hyperhomocystei | 2003 |
[Effect of betaine on hepatic steatosis of dietary origin in the rat].
Topics: Animals; Betaine; Diet; Fatty Liver; Glycine; Rats | 1956 |
[Effect of betaine on hepatic steatosis of dietary origin in the rat].
Topics: Animals; Betaine; Diet; Fatty Liver; Glycine; Rats | 1956 |
[Effect of betaine on hepatic steatosis of dietary origin in the rat].
Topics: Animals; Betaine; Diet; Fatty Liver; Glycine; Rats | 1956 |
[Effect of betaine on hepatic steatosis of dietary origin in the rat].
Topics: Animals; Betaine; Diet; Fatty Liver; Glycine; Rats | 1956 |
[Effect of betaine, administered parenterally, on hepatic steatosis].
Topics: Betaine; Choline; Fatty Liver | 1957 |
Kwashiorkor type of fatty liver in primates.
Topics: Animals; Betaine; Body Weight; Choline; Diet; Dietary Supplements; Fatty Liver; Kwashiorkor; Lipids; | 1958 |
THE EFFECTS OF CHOLINE AND RELATED COMPOUNDS ON THE GROWTH AND DEVELOPMENT OF DROSOPHILA MELANOGASTER.
Topics: Amino Acids; Amino Alcohols; Ammonium Compounds; Animals; Betaine; Carnitine; Chemical Phenomena; Ch | 1965 |
Betaine and nonalcoholic steatohepatitis.
Topics: Betaine; Fatty Liver; Humans; Lipotropic Agents; Pilot Projects | 2003 |
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease.
Topics: Animals; Betaine; Cell Division; Cells, Cultured; Cellular Senescence; DNA; DNA Repair; Fatty Liver; | 2004 |
The effect of betaine treatment on triglyceride levels and oxidative stress in the liver of ethanol-treated guinea pigs.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Betaine; Dietary Supplements; Drug Thera | 2004 |
A comparison of the effects of betaine and S-adenosylmethionine on ethanol-induced changes in methionine metabolism and steatosis in rat hepatocytes.
Topics: Animals; Betaine; Disease Models, Animal; Ethanol; Fatty Liver; Hepatocytes; Male; Methionine; Methy | 2005 |
Metabolic profiling of livers and blood from obese Zucker rats.
Topics: Animals; Betaine; Energy Metabolism; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fatty L | 2006 |
Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia.
Topics: Animals; Animals, Genetically Modified; Aorta; Apolipoprotein A-I; Betaine; Cholesterol; Disease Mod | 2007 |
Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Betaine; Cell Line; Dietary Carbohyd | 2007 |
Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes.
Topics: Animals; Apolipoproteins B; Betaine; Betaine-Homocysteine S-Methyltransferase; Carcinoma, Hepatocell | 2007 |
Carnitine transport defect in fibroblasts of juvenile visceral steatosis (JVS) mouse.
Topics: Animals; Betaine; Biological Transport; Carnitine; Cells, Cultured; Fatty Liver; Fetus; Fibroblasts; | 1996 |
Hypertriglyceridemia and fatty liver of fasting rats after administration of emeriamine.
Topics: Animals; Betaine; Carnitine; Carnitine Acyltransferases; Enzyme Inhibitors; Esterification; Fasting; | 1996 |
Effects of refeeding diets on emeriamine-induced fatty liver in fasting rats.
Topics: Animals; Betaine; Carnitine; Carnitine Acyltransferases; Cholesterol; Dietary Carbohydrates; Dietary | 1996 |
Reduction of carbon tetrachloride-induced hepatotoxic effects by oral administration of betaine in male Han-Wistar rats: a morphometric histological study.
Topics: Administration, Oral; Animals; Betaine; Carbon Tetrachloride; Fatty Liver; Gastrointestinal Agents; | 2000 |
Betaine: an old therapy for a new scourge.
Topics: Betaine; Fatty Liver; Hepatitis; Humans; Lipotropic Agents; Methylation | 2001 |
[Clinical experience with betain citrate (author's transl)].
Topics: Adult; Aged; Betaine; Citrates; Fatty Liver; Female; Humans; Hyperbilirubinemia; Leucyl Aminopeptida | 1973 |
[Clinical results using betaine citrate (Flacar) in fatty livers].
Topics: Animals; Betaine; Citrates; Diet, Reducing; Fatty Liver; Female; Humans; Male; Obesity; Rats | 1973 |
[Stea 16].
Topics: Adolescent; Adult; Aged; Betaine; Butyrates; Cholagogues and Choleretics; Cholestasis; Cyclohexanes; | 1972 |
[A new biochemical aspect of liver therapy].
Topics: Betaine; Fatty Liver; Humans; Liver Diseases | 1971 |
[Urinary elimination of 17-ketosteroids in experimental steatosis due to cholesterin and in steatosis due to cholesterin treated with methylating substances, testosterone and vitamin E (experimental research)].
Topics: 17-Ketosteroids; Animals; Betaine; Cholesterol; Choline; Fatty Liver; Quaternary Ammonium Compounds; | 1964 |
[Betaine aspartate in the hepato-digestive domain].
Topics: Aspartic Acid; Betaine; Dyspepsia; Fatty Liver; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; | 1966 |